Related Experiment Video
Updated: Oct 24, 2025

09:02
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
2.9K
Modification of Nanoparticles with Transferrin for Targeting Brain Tissues
Sara Aly Attia1, Xiang Li1,2, Nina Filipczak1
1Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA, USA.
Methods in Molecular Biology (Clifton, N.J.)
|August 13, 2021
Summary
This study details a method using transferrin protein to target nanoparticles to the brain. This approach aims to improve drug delivery across the blood-brain barrier for neuropathology treatments.
Area of Science:
- Neuroscience
- Biotechnology
- Drug Delivery
Background:
- Delivering therapeutics to brain tissues presents a significant challenge in neuropathology.
- The blood-brain barrier (BBB) restricts the passage of most molecules into the brain.
- The transferrin receptor, highly expressed on brain endothelial cells, is a key target for BBB drug delivery systems.
Purpose of the Study:
- To describe a protocol for surface-functionalizing nanoparticles with transferrin protein.
- To enhance nanoparticle uptake by brain tissues via transferrin receptor-mediated endocytosis.
- To provide a method for targeted brain drug delivery.
Main Methods:
- Functionalizing nanoparticles with transferrin protein using an amide linker.
- Coupling transferrin to PEGylated lipids, common in nanoparticle formulations.
- Utilizing transferrin receptor targeting for enhanced brain uptake.
Main Results:
- Demonstrated a method to attach transferrin to nanoparticle surfaces.
- Established a strategy for directing nanoparticles to the brain.
- Facilitated targeted delivery of nanoparticles across the blood-brain barrier.
Conclusions:
- Transferrin-functionalized nanoparticles offer a promising strategy for brain drug delivery.
- This method can be applied to various nanoparticle systems like liposomes and micelles.
- The protocol provides a foundation for developing novel neuropathology therapeutics.

